Repare Therapeutics Inc
RPTX1.495USD
-0.005-0.33%
交易中 （美东）报价延迟15分钟
64.12M总市值
亏损市盈率 TTM
关于 Repare Therapeutics Inc 公司
Repare Therapeutics Inc. 是一家临床阶段精准肿瘤学公司，通过其专有的合成致死法来发现和开发新型疗法。该公司利用其全基因组、支持 CRISPR 的 SNIPRx 平台系统地发现和开发高度针对性的癌症疗法，重点是基因组不稳定性，包括 DNA 损伤修复。其产品线包括 lunresertib (RP-6306)，一种处于 1/2 期临床开发的 PKMYT1 抑制剂；camonsertib (RP-3500)，一种潜在的共济失调毛细血管扩张症和 Rad3 相关蛋白激酶 (ATR) 抑制剂，处于 1/2 期临床开发；RP-1664，一种 1 期 PLK4 抑制剂；RP-3467，一种临床前聚合酶 θ 腺苷三磷酸酶 (ATPase) 抑制剂项目，以及其他未公开的临床前项目。 RP-3500 是一种强效、选择性口服小分子 ATR 抑制剂，目前正处于临床开发阶段，用于治疗具有特定 DNA 损伤修复相关基因组改变的实体肿瘤。
公司简介
公司代码RPTX
公司名称Repare Therapeutics Inc
上市日期Jun 19, 2020
CEOMr. Steve Forte
员工数量129
证券类型Ordinary Share
年结日Jun 19
公司地址7210 Frederick-Banting, Suite 100
城市ST-LAURENT
上市交易所NASDAQ Global Select Consolidated
国家Canada
邮编H4S 2A1
电话18574127018
网址https://www.reparerx.com/
公司代码RPTX
上市日期Jun 19, 2020
CEOMr. Steve Forte
公司高管
名称
名称/职务
职务
持股
持股变动
Dr. Michael Zinda, Ph.D.
Dr. Michael Zinda, Ph.D.
Executive Vice President, Chief Scientific Officer
Executive Vice President, Chief Scientific Officer
48.78K
-16.35%
Ms. Sandra Alves
Ms. Sandra Alves
Senior Vice President, Chief Accounting Officer
Senior Vice President, Chief Accounting Officer
29.62K
+16.06%
Mr. Steve Forte
Mr. Steve Forte
President, Chief Executive Officer, Chief Financial Officer, Director
President, Chief Executive Officer, Chief Financial Officer, Director
23.28K
+32.63%
Ms. Carol Anne Schafer
Ms. Carol Anne Schafer
Independent Director
Independent Director
8.00K
--
Mr. Thomas Civik
Mr. Thomas Civik
Independent Chairman of the Board
Independent Chairman of the Board
7.50K
--
Ms. Ann D. Rhoads
Ms. Ann D. Rhoads
Independent Director
Independent Director
4.00K
--
Dr. Susan M. Molineaux, Ph.D.
Dr. Susan M. Molineaux, Ph.D.
Independent Director
Independent Director
--
--
Dr. Steven H. Stein, M.D.
Dr. Steven H. Stein, M.D.
Independent Director
Independent Director
--
--
Dr. David P. Bonita, M.D.
Dr. David P. Bonita, M.D.
Independent Director
Independent Director
--
--
Dr. Samarth Kulkarni, Ph.D.
Dr. Samarth Kulkarni, Ph.D.
Independent Director
Independent Director
--
--
名称
名称/职务
职务
持股
持股变动
Dr. Michael Zinda, Ph.D.
Dr. Michael Zinda, Ph.D.
Executive Vice President, Chief Scientific Officer
Executive Vice President, Chief Scientific Officer
48.78K
-16.35%
Ms. Sandra Alves
Ms. Sandra Alves
Senior Vice President, Chief Accounting Officer
Senior Vice President, Chief Accounting Officer
29.62K
+16.06%
Mr. Steve Forte
Mr. Steve Forte
President, Chief Executive Officer, Chief Financial Officer, Director
President, Chief Executive Officer, Chief Financial Officer, Director
23.28K
+32.63%
Ms. Carol Anne Schafer
Ms. Carol Anne Schafer
Independent Director
Independent Director
8.00K
--
Mr. Thomas Civik
Mr. Thomas Civik
Independent Chairman of the Board
Independent Chairman of the Board
7.50K
--
Ms. Ann D. Rhoads
Ms. Ann D. Rhoads
Independent Director
Independent Director
4.00K
--
收入明细
暂无数据
暂无数据
业务
地区
暂无数据
股东统计
更新时间: 8月1日 周五
更新时间: 8月1日 周五
持股股东
股东类型
持股股东
持股股东
占比
BVF Partners L.P.
24.09%
Blue Owl Capital Holdings LP
7.86%
OrbiMed Advisors, LLC
7.46%
Versant Ventures
6.92%
Redmile Group, LLC
4.39%
Other
49.27%
持股股东
持股股东
占比
BVF Partners L.P.
24.09%
Blue Owl Capital Holdings LP
7.86%
OrbiMed Advisors, LLC
7.46%
Versant Ventures
6.92%
Redmile Group, LLC
4.39%
Other
49.27%
股东类型
持股股东
占比
Hedge Fund
27.84%
Investment Advisor/Hedge Fund
15.21%
Investment Advisor
11.59%
Private Equity
7.55%
Venture Capital
6.92%
Individual Investor
1.41%
Research Firm
0.27%
Family Office
0.09%
Other
29.13%
机构持股
更新时间: 7月1日 周二
更新时间: 7月1日 周二
报告期
机构数
持股数
持股占比
持股变动
2025Q2
171
32.21M
75.10%
-8.67M
2025Q1
185
33.16M
77.30%
-8.74M
2024Q4
193
34.29M
80.67%
-8.93M
2024Q3
196
36.17M
85.09%
-7.71M
2024Q2
200
37.54M
88.44%
-7.90M
2024Q1
203
39.40M
93.34%
-5.92M
2023Q4
206
40.21M
95.29%
-816.82K
2023Q3
207
37.21M
88.27%
-2.03M
2023Q2
203
37.24M
88.48%
-4.72M
2023Q1
213
37.90M
90.09%
-4.89M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
BVF Partners L.P.
10.33M
24.09%
--
--
Apr 15, 2025
Blue Owl Capital Holdings LP
3.37M
7.86%
-71.16K
-2.07%
Apr 15, 2025
OrbiMed Advisors, LLC
3.20M
7.46%
-122.13K
-3.68%
Apr 15, 2025
Versant Ventures
2.97M
6.92%
+321.00K
+12.13%
Apr 15, 2025
Redmile Group, LLC
1.88M
4.39%
-31.70K
-1.65%
Mar 31, 2025
Aquilo Capital Management, LLC
1.29M
3.02%
--
--
Mar 31, 2025
MPM Capital Inc.
1.12M
2.61%
-819.92K
-42.24%
Mar 31, 2025
Citadel Advisors LLC
937.49K
2.19%
+937.49K
--
Mar 31, 2025
MPM BioImpact LLC
819.92K
1.91%
-411.23K
-33.40%
Mar 31, 2025
Acadian Asset Management LLC
640.33K
1.49%
+168.23K
+35.63%
Mar 31, 2025
查看更多
持股ETF
更新时间: 8月2日 周六
更新时间: 8月2日 周六
机构名称
占比
Invesco Nasdaq Biotechnology ETF
0%
ProShares Ultra Nasdaq Biotechnology
0%
DFA Dimensional US Core Equity Market ETF
0%
Avantis US Equity ETF
0%
Dimensional US Core Equity 1 ETF
0%
SPDR S&P International Small Cap ETF
0%
Fidelity MSCI Health Care Index ETF
0%
SPDR Portfolio MSCI Global Stock Market ETF
0%
Avantis US Small Cap Equity ETF
0%
ARK Genomic Revolution ETF
0%
查看更多
Invesco Nasdaq Biotechnology ETF
占比0%
ProShares Ultra Nasdaq Biotechnology
占比0%
DFA Dimensional US Core Equity Market ETF
占比0%
Avantis US Equity ETF
占比0%
Dimensional US Core Equity 1 ETF
占比0%
SPDR S&P International Small Cap ETF
占比0%
Fidelity MSCI Health Care Index ETF
占比0%
SPDR Portfolio MSCI Global Stock Market ETF
占比0%
Avantis US Small Cap Equity ETF
占比0%
ARK Genomic Revolution ETF
占比0%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据
